BenevolentAI has raised $90 million from Temasek, a Singapore-headquartered investment company. The funding will be used to scale and further develop the Benevolent Platform for drug discovery and development as well as further progress BenevolentAI drug programmes developed in-house and through collaborations.
BenevolentAI have collaborated with Novartis Global Drug Development on an initial project in oncology, which will see the application of our AI and machine learning technology to stratify patients and gain a better understanding of patient and disease heterogeneity to more precisely target medicines for patients who need them
Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence
The initial results from an artificial intelligence project show a number of existing drugs have the potential to reduce sight loss from age-related macular degeneration, the leading cause of sight loss.